Albumin paclitaxel injection

DRUG2 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., Chinese PLA General Hospital

Conditions

Hematologic MalignancyPancreatic NeoplasmsSolid Tumor

Phase 1

Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors.

RecruitingNCT07570563

Chinese PLA General HospitalHematologic Malignancy, Solid Tumor

Start: 2026-06-05End: 2031-12-31Target: 24Updated: 2026-06-08

Phase 2

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

RecruitingNCT06767813

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Pancreatic Neoplasms

Start: 2024-03-19End: 2026-11-30Target: 80Updated: 2025-09-19

Related Papers

TQB2868 combined with anlotinib and nab-paclitaxel plus gemcitabine as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.

Journal of Clinical Oncology2025-05-28